European RWE & Market Access
Summit 2026
JCA & PICO Strategy Edition
October 21-22 | Amsterdam
Inntel Hotels Amsterdam Landmark
- 00Days
- 00Hours
- 00Minutes
Wlcus
European RWE & Market Access Summit 2026,
October 21-22.
The 2nd Annual European RWE & Market Access Summit 2026 is the pharmaceutical industry’s definitive Implementation War Room, designed to navigate the high-stakes transition into the New European HTA Era. As Joint Clinical Assessments (JCA) become mandatory for oncology and ATMPs, the mission of this summit is to provide Market Access, HEOR, and RWE leaders with a technical roadmap for the critical 100-day submission window.
This specialized 2026 edition moves beyond theory, delivering actionable insights into PICO strategy (Population, Intervention, Comparator, and Outcome), bias mitigation, and the operationalization of DARWIN EU 2.0 for regulatory-grade evidence generation. By attending, cross-functional teams will master national HTA readiness, aligning global evidence planning with EMA technical requirements and multi-state payer priorities. From Evidence-to-Access frameworks to solving PICO anxiety, this summit is the essential briefing for ensuring your 2026–2028 pipeline achieves successful reimbursement and long-term market sustainability across Europe.
2026 Strategic Focus
Why This Summit is the Industry’s Definitive “Don’t-Miss” Briefing
JCA Submission Mastery
Navigate the high-stakes transition into mandatory Joint Clinical Assessments with a tactical roadmap for oncology and ATMP dossiers. Gain the “how-to” on meeting aggressive timelines and ensuring your evidence package is fully compliant with the new 100-day submission window.
PICO Scoping & Strategy
Eliminate “PICO anxiety” by learning predictive frameworks to anticipate the Population, Intervention, Comparator, and Outcome requirements of diverse Member States. Master the art of bias mitigation and statistical alignment to prevent costly delays in your submission process.
DARWIN EU 2.0 Operations
Get a direct technical briefing on the EMA’s DARWIN EU network and its transformative role in multi-state data interoperability. Learn to generate “regulatory-grade” evidence that meets the highest standards of data quality and scientific integrity for 2026–2028.
National HTA Alignment
Solve the challenge of national divergence by aligning global RWE strategies with the specific priorities of local payers and HTA bodies. Transition from broad data collection to precision evidence that addresses country-specific pricing and reimbursement hurdles.
AI-Driven Evidence Synthesis
Explore the commercial integration of AI and machine learning to streamline RWE operations and automate complex data synthesis. Discover how to reduce the “data-to-submission” lifecycle, providing your cross-functional teams a competitive edge in rapid-response environments.
Payer & Regulator Networking
Break down organizational silos by engaging in closed-door discussions with the key architects of the European HTA landscape. Build the high-level networks necessary to influence policy, understand payer sentiment, and secure long-term market sustainability for your pipeline.
European RWE & Market Access Summit 2026
Who Should Attend?
Join the Summit on October 21-22 in Amsterdam, Netherlands
- Pharmaceutical Companies
- Bio-Pharma Companies
- RWE / HEOR Directors & Leads
- Market Access Directors & Senior Managers
- Pricing & Reimbursement Leaders
- Medical Affairs
- Evidence Strategy Teams
- Regulatory Strategy Teams
- HTA Assessors
- Real World Data - RWD
- Real World Evidence - RWE
- Payer Decision Makers
- Policy Makers
- Evidence Reviewers
- AI in HealthCare Experts
- RWD Platform Providers
- Digital Therapeutics Companies
- Federated Data Networks
- Evidence Technology Innovators
- HEOR Modelling Experts
- Evidence Specialists
- Health Economists
- Access Researchers
Our RWE & Pricing Event 2026, Stats:
Meet the Conference Speakers & Thought Leaders
Our Prestigious Panel of Speakers
The Chair
Dr. Vivian Mendonca
SVP- Global Head - Commercial Strategy, Access, Pricing, HEOR, CDx, Policy and Patient Engagement
MENARINI Group
Yvette Venable
Global Director, Payer Partnerships & Policy, Global Market Access & Pricing
AstraZeneca
Lora Fleifel
Market Access and Pricing
Operations Director- Specialty Care
and Rare Tumors- Core Markets
Join the EU moment Now!
Event 2026 Sponsors, Exhibitors & Partners
DLRC Group is a leading life sciences consultancy specializing in Regulatory Affairs, HTA, and Market Access strategy for pharmaceutical, biotechnology, medical device, and healthcare companies. With offices in the UK, Germany, and the US, DLRC supports organizations from early development through commercialization and lifecycle management. Their expertise includes regulatory strategy, evidence planning, HTA submissions, reimbursement pathways, payer engagement, and market access optimization. DLRC helps clients navigate complex global regulatory and access requirements, ensuring products reach patients efficiently. Their strong focus on evidence generation, HTA readiness, and market access makes them highly relevant to organizations operating within the evolving EU-HTA and Real- World Evidence landscape.
Cellbyte is an AI-native platform helping pharmaceutical companies accelerate global drug launches by transforming complex pricing, market access, HTA, regulatory, and clinical data into actionable insights. Its intelligent AI agents automate time-consuming workflows, enabling faster, more informed decision-making across the product commercialization lifecycle. Trusted by leading pharmaceutical organizations, Cellbyte empowers Market Access, HEOR, Pricing, and Commercial teams to streamline launch planning, optimize reimbursement strategies, and improve cross-functional collaboration. By combining advanced AI with comprehensive, continuously updated global healthcare data, Cellbyte enables organizations to reduce manual effort, enhance strategic planning, and bring innovative therapies to patients faster across international markets
Ingenious e-Brain Solutions (IEBS) is a global management consulting and intelligence firm with 14+ years of experience supporting leading life sciences and healthcare organizations. We help clients navigate complex RWE, market access, HEOR, HTA, pricing & reimbursement, and JCA challenges through deep domain expertise, advanced analytics, AI, and technology. With 5,000+ engagements and partnerships with 50+ Fortune 500 and Global 2000 organizations, we combine proven expertise with agile, scalable delivery. As market access evolves toward
faster evidence generation and more integrated HTA frameworks, IEBS is transforming its heritage into velocity-using AI, automation, and advanced analytics to accelerate insights, strengthen evidence strategies, and enable faster, smarter patient access.
Velora Evidence is an evidence generation and medical affairs consultancy. We build integrated evidence generation plans through facilitated workshops, and support the execution of the real-world studies that follow, whether observational, registry based, patient reported, or drawn from claims and linked health data. We provide strategic and operational oversight from design and protocol through to analysis and publication strategy.
Bridges2Access partners with pharmaceutical, biotechnology, and medical technology companies to accelerate patient access through expert support in Market Access, HEOR, HTA, Evidence Generation, Pricing & Reimbursement, and Health Policy. With flexible senior-level consulting, they help organizations develop evidence-based strategies that strengthen value, support payer engagement, and improve commercial success.
Register Now!
